Antibiotic resistance in Ureaplasma urealyticum/Ureaplasma parvum and Mycoplasma hominis is an issue of increasing importance. However, data regarding the susceptibility and, more importantly, the clonality of these organisms are limited. We analyzed 140 genital samples obtained in Bern, Switzerland, in 2014. Identification and antimicrobial susceptibility tests were performed by using the Mycoplasma IST 2 kit and sequencing of 16S rRNA genes. MICs for ciprofloxacin and azithromycin were obtained in broth microdilution assays. Clonality was analyzed with PCR-based subtyping and multilocus sequence typing (MLST), whereas quinolone resistance and macrolide resistance were studied by sequencing gyrA, gyrB, parC, and parE genes, as well as 23S rRNA genes and genes encoding L4/L22 ribosomal proteins. A total of 103 samples were confirmed as positive for U. urealyticum/U. parvum, whereas 21 were positive for both U. urealyticum/U. parvum and M. hominis. According to the IST 2 kit, the rates of nonsusceptibility were highest for ciprofloxacin (19.4%) and ofloxacin (9.7%), whereas low rates were observed for clarithromycin (4.9%), erythromycin (1.9%), and azithromycin (1%). However, inconsistent results between microdilution and IST 2 kit assays were recorded. Various sequence types (STs) observed previously in China (ST1, ST2, ST4, ST9, ST22, and ST47), as well as eight novel lineages, were detected. Only some quinolone-resistant isolates had amino acid substitutions in ParC (Ser83Leu in U. parvum of serovar 6) and ParE (Val417Thr in U. parvum of serovar 1 and the novel Thr417Val substitution in U. urealyticum). Isolates with mutations in 23S rRNA or substitutions in L4/L22 were not detected. This is the first study analyzing the susceptibility of U. urealyticum/U. parvum isolates in Switzerland and the clonality outside China. Resistance rates were low compared to those in other countries. We hypothesize that some hyperepidemic STs spread worldwide via sexual intercourse. Large combined microbiological and clinical studies should address this important issue.
women; 40% of them were coinfected/colonized with M. hominis (11) . Overall, most of the published studies comparing adverse pregnancy outcomes showed significant associations with the presence of U. urealyticum or M. hominis (3) .
Due to the lack of peptidoglycan, Ureaplasma spp. and Mycoplasma spp. are naturally resistant to ␤-lactams, whereas sulfonamides and trimethoprim are inactive because of the absence of folic acid synthesis. In general, these pathogens are considered susceptible to tetracyclines, fluoroquinolones (FQs), and macrolides (3) . Acquired resistance against several of these classes has been described, but studies on the antimicrobial susceptibility profiles and resistance mechanisms of genital mycoplasmas are still scarce and cover only some geographic regions (8) (9) (10) (11) (12) (13) (14) (15) .
To our knowledge, data on the antimicrobial susceptibility of genital mycoplasmas isolated in Switzerland are completely lacking. More importantly, information concerning the spread of spe-
RESULTS AND DISCUSSION
In the past decade, U. urealyticum, U. parvum, and M. hominis have received increased attention because of their associations with urogenital infections, adverse pregnancy outcomes, preterm birth, and postpartum infections (1) (2) (3) . Due to the frequent implementation of molecular tests that only identify the causative pathogens (22) , these clinical conditions are usually treated with empirical therapy based on the use of macrolides, tetracyclines, or FQs (23, 24) . However, data regarding the antibiotic susceptibility patterns of genital mycoplasmas are scarce, and local statistics particularly are needed to establish effective treatments. Therefore, one goal of the present study was to analyze for the first time the antimicrobial susceptibility profiles of contemporary genital mycoplasma isolates collected in Switzerland.
Of 140 samples, 103 (74%) were confirmed to be positive for U. urealyticum/U. parvum, whereas 21 (15%) were positive for both U. urealyticum/U. parvum and M. hominis. Since no pure cultures of M. hominis were obtained (and their numbers were small), only AST results for U. urealyticum/U. parvum were considered. As shown in Fig. 1 (24) .
We also positively note that the overall Swiss resistance rates seem to be low, compared to those for other countries. For instance, a recent Italian study investigating U. urealyticum strains isolated from female genital samples indicated the following resistance rates: CIP, 41%; ERY, 19%; CLA, 15%; OFL, AZI, TET, DOX, JOS, and PRI overall, Ͻ10% (12). Another Italian study, from De Francesco et al., obtained consistent results (10) . Two Chinese analyses reported FQ resistance rates of Ͼ40% for Ureaplasma spp., while rates of resistance to macrolides and tetracyclines were Ͻ30% and Ͻ10%, respectively (8, 9) . In South Africa, Ureaplasma isolates had the following resistance rates: levofloxacin, 41%; moxifloxacin, 2%; ERY, 80%; TET, 73% (11) . In Croatia, U. urealyticum strains showed nonsusceptibility rates of 22%, 8%, and 3% for OFL, AZI, and DOX, respectively (14) . However, we emphasize that possible inconsistencies in resistance rates among the aforementioned studies could occur due to the use of different methodologies (i.e., Mycoplasma IST 2 kit [10, 12, 13] versus broth microdilution [25] ) and/or different criteria for interpretation for the susceptibility results (i.e., those used for the Mycoplasma IST 2 kit [10, 12, 13] versus those of the CLSI [9, 11, 19] ). As shown in this work (Table 1) , conflicting results from the IST 2 kit and standard broth microdilution were observed for CIP and AZI (i.e., most of the isolates routinely reported as nonsusceptible to these antibiotics were actually fully sensitive). Therefore, rates of nonsusceptibility to FQs and macrolides might be overestimated using the IST 2 kit. Larger comparative studies should address these clinically important discrepancies.
Overall, in most countries the highest resistance rates have been recorded against FQs (8) (9) (10) (11) (12) (13) (14) . This is undoubtedly due to their empirical overuse in the community (e.g., for urinary and respiratory tract infections), which contributes to the selection of amino acid substitutions in the QRDRs of DNA gyrase (GyrA and GyrB) and DNA topoisomerase IV (ParC and ParE) (20, 26, 27) . h This is the first report of the Thr417Val substitution in U. urealyticum (27 In our U. parvum strains, we found the substitutions Ser83Leu in ParC and Val417Thr in ParE, whereas the previously unreported Thr417Val in ParE was detected in U. urealyticum (Table 1 ) (27) . However, we noted with surprise that only 5 of 15 CIP-nonsusceptible isolates (MICs of Ն2 g/ml by using the IST 2 kit) had amino acid substitutions in the QRDRs. This phenomenon was observed previously and was ascribed to mechanisms not yet recognized (e.g., altered membrane permeability); however, we emphasize that the IST 2 kit might overrate the FQ resistance (i.e., high MICs that are actually in the susceptible range with the microdilution method). With regard to the QRDR substitutions found in the five isolates, only the well-described Ser83Leu substitution in ParC (U. parvum ID141 [ST22 and serovar 6]) conferred resistance to CIP (MIC of 4 g/ml with the microdilution method) (25, 28) , whereas both Thr417Val (for U. urealyticum) and Val417Thr (for U. parvum) ParE substitutions had predicted small effects on the MICs (Table 1 ) (27) . Mutations in the two copies of 23S rRNA or, more frequently, amino acid substitutions in the L4 and L22 ribosomal proteins were linked previously to macrolide resistance. However, studies focusing on these molecular aspects are scarce (15, 21, (29) (30) (31) . In the present work, we analyzed the aforementioned resistance traits for four Ureaplasma isolates showing nonsusceptibility to macrolides (MICs of Ն2 g/ml for CLA or ERY with the IST 2 kit); none of the isolates possessed substitutions in L4 or L22 or mutations in the 23S rRNA copies (Table 1) . These unexpected findings may be explained by the fact that (i) our four isolates were actually susceptible to macrolides, according to the CLSI criteria (MICs of Յ8 g/ml for ERY) (19) , and (ii) all macrolide-nonsusceptible strains were truly sensitive when tested with the microdilution method, with most of the AZI MICs being Յ0.064 g/ml (Table 1 ). In contrast, Ureaplasma isolates with one of the aforementioned chromosomal mechanisms of resistance are usually highly resistant (e.g., MICs of Ն128 g/ml for ERY) (15) .
For 25 of 103 isolates (i.e., 9 U. urealyticum isolates and 16 U. parvum isolates), we also obtained the serovars and explored the distribution of STs by analyzing the isolates with a MLST method recently developed by Zhang et al. (16) . This overall information is essential for establishing whether certain Ureaplasma lineages are spreading clonally and, more importantly, whether they are associated with specific and/or more severe clinical conditions. Based on their MLST scheme, Zhang et al. (16) indicated that Ureaplasma strains from China are split into two clonal complexes, which are highly congruent with the taxonomic differences between U. parvum and U. urealyticum species. Notably, U. parvum and its two major clones (ST1 and ST22) are found more often in asymptomatic infections than U. urealyticum (e.g., ST9 and ST47). However, we note that information regarding the distribution of STs for Ureaplasma spp. is limited to the Chinese data provided by the aforementioned authors (14 reference strains and 269 isolates analyzed), and nothing is known about other geographical regions (16, 32) .
As shown in Table 1 , our results indicate that, although numerous new STs in both U. urealyticum (from ST100 to ST102) and U. parvum (from ST103 to ST107) were identified, the main Ureaplasma clones recently observed in China are also present among Swiss people. In particular, ST4 (including serovars 1, 6, and 3/14) was the most prevalent among U. parvum isolates, but ST1 (serovar 3/14), ST2 (serovar 1), ST22 (serovar 6), ST38 (serovar 3/14), and ST58 (serovar 1) were also detected. With regard to U. urealyticum, unique ST9 (subtype 2), ST47 (subtype 1), and ST54 (not typeable with the PCR methodology implemented) isolates were found. Therefore, according to the MLST findings, the two patient populations (Chinese and Swiss) share several clones of U. parvum and U. urealyticum. This finding raises the question of whether specific hyperepidemic lineages of Ureaplasma spp. can spread worldwide (e.g., via sexual intercourse) and then adapt themselves well to the urogenital tracts of different populations. In support of this speculation, the phylogenetic analysis performed using MEGA 5.0 with 6 U. urealyticum and 11 U. parvum isolates with different STs indicated that most of the novel STs found in the present study are strongly related to the ancestors (ST1 for U. parvum and ST47 for U. urealyticum) and to the very prevalent Chinese variants (e.g., ST4, ST9, and ST22) (Fig. 2) .
In conclusion, this study fills up the lack of Swiss data regarding the antibiotic susceptibility of Ureaplasma spp. responsible for urogenital infections, indicating a lower prevalence of resistant isolates, compared to other countries. We surprisingly detected numerous STs already observed in China, but these intriguing results could not be matched with those from other geographic regions due to the complete absence of studies focusing on this matter. Unfortunately, our study does not provide adequate clinical data to establish the extent of infection or colonization and the potential link with specific STs of U. urealyticum and U. parvum among our patients. Large combined microbiological and clinical studies should address these important aspects in the near future. 
